168 related articles for article (PubMed ID: 29878937)
1. Clinical Profile of a Nonselected Population Treated With Sacubitril/Valsartan Is Different From PARADIGM-HF Trial.
Vicent L; Esteban-Fernández A; Gómez-Bueno M; De-Juan J; Díez-Villanueva P; Iniesta ÁM; Ayesta A; González-Saldívar H; Rojas-González A; Bover-Freire R; Iglesias D; García-Aguado M; Perea-Egido JA; Martínez-Sellés M
J Cardiovasc Pharmacol; 2018 Aug; 72(2):112-116. PubMed ID: 29878937
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry.
Vicent L; Esteban-Fernández A; Gómez-Bueno M; De-Juan J; Díez-Villanueva P; Iniesta ÁM; Ayesta A; González-Saldívar H; Rojas-González A; Bover-Freire R; Iglesias D; García-Aguado M; Perea-Egido JA; Martínez-Sellés M
J Cardiovasc Pharmacol; 2019 Feb; 73(2):118-124. PubMed ID: 30540687
[TBL] [Abstract][Full Text] [Related]
3. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
[TBL] [Abstract][Full Text] [Related]
4. Representativeness of the PIONEER-HF Clinical Trial Population in Patients Hospitalized With Heart Failure and Reduced Ejection Fraction.
Fudim M; Sayeed S; Xu H; Matsouaka RA; Heidenreich PA; Velazquez EJ; Yancy CW; Fonarow GC; Hernandez AF; DeVore AD
Circ Heart Fail; 2020 Apr; 13(4):e006645. PubMed ID: 32248695
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial.
DeVore AD; Mi X; Thomas L; Sharma PP; Albert NM; Butler J; Hernandez AF; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Fonarow GC
J Am Heart Assoc; 2018 Jun; 7(12):. PubMed ID: 29895587
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Neprilysin Inhibitor for Patients With Heart Failure and Reduced Ejection Fraction: Real-World Experience From Taiwan.
Hsiao FC; Wang CL; Chang PC; Lu YY; Huang CY; Chu PH
J Cardiovasc Pharmacol Ther; 2020 Mar; 25(2):152-157. PubMed ID: 31514513
[TBL] [Abstract][Full Text] [Related]
7. Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review.
Moliner-Abós C; Rivas-Lasarte M; Pamies Besora J; Fluvià-Brugues P; Solé-González E; Mirabet S; López López L; Brossa V; Pirla MJ; Mesado N; Álvarez-García J; Roig E
Cardiovasc Drugs Ther; 2019 Jun; 33(3):307-314. PubMed ID: 30820802
[TBL] [Abstract][Full Text] [Related]
8. The eligible population of the PARADIGM-HF trial in a real-world outpatient clinic and its cardiovascular risk between 2005 and 2016.
Chen X; Schaufelberger M; Fu M
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):6-12. PubMed ID: 31789711
[TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
10. Understanding the early mortality benefit observed in the PARADIGM-HF trial: considerations for the management of heart failure with sacubitril/valsartan.
Sokos GG; Raina A
Vasc Health Risk Manag; 2020; 16():41-51. PubMed ID: 32021227
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril-Valsartan for the Treatment of Heart Failure: Time for a Paragon?
Del Buono MG; Bonaventura A; Vecchié A; Wohlford GF; Dixon DL; Van Tassel BW; Abbate A
J Cardiovasc Pharmacol; 2020 Feb; 75(2):105-107. PubMed ID: 31815825
[No Abstract] [Full Text] [Related]
12. Is the glass half full or half empty after PARAGON-HF?
Cohen-Solal A; Logeart D
Cardiovasc Res; 2020 Jan; 116(1):e5-e7. PubMed ID: 31850504
[No Abstract] [Full Text] [Related]
13. Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States.
DeVore AD; Hill CL; Thomas L; Sharma PP; Albert NM; Butler J; Patterson JH; Spertus JA; Williams FB; Duffy CI; McCague K; Hernandez AF; Fonarow GC
Circ Heart Fail; 2018 Sep; 11(9):e005400. PubMed ID: 30354360
[TBL] [Abstract][Full Text] [Related]
14. Effects of sacubutril/valsartan on nutritional status in heart failure with reduced ejection fraction.
Dereli S; Bayramoğlu A; Kaya A
J Cardiovasc Med (Hagerstown); 2020 Jan; 21(1):13-20. PubMed ID: 31714330
[TBL] [Abstract][Full Text] [Related]
15. Profile of sacubitril/valsartan in the treatment of heart failure: patient selection and perspectives.
Yandrapalli S; Andries G; Biswas M; Khera S
Vasc Health Risk Manag; 2017; 13():369-382. PubMed ID: 29042791
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin Receptor-Neprilysin Inhibition.
Havakuk O; Elkayam U
J Cardiovasc Pharmacol Ther; 2017 Jul; 22(4):356-364. PubMed ID: 28587583
[TBL] [Abstract][Full Text] [Related]
17. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
[TBL] [Abstract][Full Text] [Related]
18. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
19. In-Hospital Initiation of Sacubitril/Valsartan: A New PARADIGM for Acute Decompensated Heart Failure?
Bonaventura A; Wohlford GF; Vecchié A; Van Tassel BW; Abbate A
J Cardiovasc Pharmacol; 2019 Jul; 74(1):1-3. PubMed ID: 31274835
[No Abstract] [Full Text] [Related]
20. Effects of angiotensin receptor neprilysin inhibition on pulmonary arterial stiffness in heart failure with reduced ejection fraction.
Yenerçağ M; Arslan U; Dereli S; Çoksevim M; Doğduş M; Kaya A
Int J Cardiovasc Imaging; 2021 Jan; 37(1):165-173. PubMed ID: 32815051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]